- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07945431
A Study Evaluating the Efficacy and Safety of Novel Non-Opioid SRP-001 in Acute Pain After Molar Extraction
A Phase 2 Randomized, Double-blind, Placebo-controlled Study Assessing Analgesic Efficacy and Safety of the Novel Non-opioid SRP-001 Compared to Placebo in Patients With Moderate-to-severe Acute Postoperative Pain After Impacted Third Mandibular Molar Extraction
This study tests whether a single oral dose of SRP-001 (2,000 mg), a non-opioid drug, relieves moderate-to-severe pain after surgery to remove impacted third molars (wisdom teeth), compared with placebo. It also evaluates safety and how the body processes the drug.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is a single-center, randomized, double-blind, placebo-controlled, parallel-group Phase 2 study evaluating the analgesic efficacy, onset of action, pharmacokinetics, and safety of a single oral dose of SRP-001 (2,000 mg oral suspension) compared to matching placebo in 130 adult participants experiencing moderate-to-severe acute postoperative pain (NPRS ≥ 5 and categorical pain ≥ 2 within 4.5 hours) following extraction of two or more third molars (including at least two bone-impacted mandibular molars). Participants remain in the clinical research unit for 12 hours post-dose for serial efficacy, double-stopwatch onset, safety, and pharmacokinetic assessments, followed by 24-hour rescue diary tracking (two-tiered rescue: ibuprofen 400 mg, then oxycodone 5 mg if needed) and an in-person safety follow-up visit on Day 8 (± 2 days).
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Todd Bertoch, MD
- Telefoonnummer: 928 830 7354
- E-mail: t.bertoch@cenexel.com
Studie Contact Back-up
- Naam: CenExel JBR Recruiting
Studie Locaties
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84107
- CenExel JBR Clinical Research
-
Contact:
- Todd M Burtoch, MD
- Telefoonnummer: 2303 (801) 261-2000
- E-mail: t.bertoch@cenexel.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Is male or female ≥ 18 and ≤ 50 years of age.
- Requires extraction of 2 or more third molars. At least 2 of the third molars must be a fully or partially bone impacted mandibular molar.
- Experiences moderate-to-severe pain defined as a score ≥ 2 on the 4-point categorical scale, and a score of ≥ 5 measured by the 0-10 Numeric Pain Rating Scale (NPRS) within 4.5 hours after surgery.
- Has a body weight ≥ 45 kg and a body mass index (BMI) ≤ 35 kg/m2.
- Female subjects of child-bearing potential must have used an acceptable method of contraception for at least 30 days prior to randomization and agree to continue use until at least 48 hours post-discharge from the clinic. To be considered not of child-bearing potential, females must be surgically sterile (defined as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or post-menopausal (defined as no menses for 12 months without an alternative medical cause).
- Free of clinically significant abnormal findings as determined by medical history, physical examination, vital signs, and laboratory tests.
- Able to provide written informed consent.
- Is willing and able to comply with study requirements (including diet and smoking restrictions), complete the pain evaluations, remain at the study site for 12 hours post-dose on Day 1, and complete an in-person follow-up visit on Day 8 (± 2 days)
Exclusion Criteria:
- Known hypersensitivity or allergy to acetaminophen, NSAIDs (including ibuprofen), aspirin, study drug ingredients, anesthetics, or antibiotics.
- History of active or previous peptic ulceration, gastrointestinal bleeding or perforation, heart failure, renal impairment, uncontrolled hypertension, exercise-induced asthma, nasal polyps, or chronic rhinitis; or history or presence of hepatic impairment, or clinically significant baseline laboratory abnormalities at Screening, defined as serum ALT or AST > 1.5× the Upper Limit of Normal (ULN), or total bilirubin > 1.5× ULN (unless attributable to documented Gilbert's syndrome), uncontrolled hypertension, exercise-induced asthma, nasal polyps, or chronic rhinitis.
- Complications from tooth extraction resulting in a "severe" surgical trauma rating.
- Dental surgery within 60 days prior to Day 1.
- Positive urine drug screen or alcohol breathalyzer test.
- Positive pregnancy test (serum at screening, urine pre-surgery on Day 1) or lactating.
- Known history or suspected (in the opinion of the investigator) of alcoholism or drug abuse within 2 years.
- Concomitant medications that confound pain assessment. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) are permitted if on a stable dose for ≥ 4 weeks prior to Screening.
- History of chronic use (defined as daily use for > 2 weeks within 6 months) of NSAIDs, opiates, or glucocorticoids for any condition within 6 months prior to dosing.
- Difficulty swallowing oral medication.
- Investigational drug exposure within 30 days or 5 half-lives.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: SRP-001
SRP-001 Single Oral Suspension dose of 2,000 mg |
SRP-001 Oral Suspension |
|
Placebo-vergelijker: Matching Placebo for SRP-001
Matching Placebo for SRP-001 Oral Suspension |
Matching Placebo for SRP-001 Oral Suspension
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Sum of Pain Intensity Differences Over 0 to 6 Hours (SPID0-6)
Tijdsspanne: 0 to 6 hours post-dose
|
Time-weighted sum of pain intensity differences from baseline over 0 to 6 hours post-dose, assessed using the 0-10 Numeric Pain Rating Scale (NPRS scale 0 -10 higher being worse) comparing SRP-001 (2,000 mg) to placebo. |
0 to 6 hours post-dose
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time-Weighted Sum of Pain Intensity Differences Over 0 to 2, 0 to 4, and 0 to 8 Hours (SPID0-2, SPID0-4, SPID0-8)
Tijdsspanne: 0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose
|
Time-weighted sum of pain intensity differences from baseline over 0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose assessed on the 0-10 NPRS (higher being worse) |
0 to 2 hours, 0 to 4 hours, and 0 to 8 hours post-dose
|
|
Sum of pain relief (TOTPAR)
Tijdsspanne: O to 2, 0 to 4, 0 to 6 and 0-8 hours.
|
Sum of pain relief (TOTPAR) from 0 to 2 (TOTPAR0-2), 0 to 4 (TOTPAR0-4), 0 to 6 hours (TOTPAR0-6), and 0 to 8 (TOTPAR0-8) post dose. |
O to 2, 0 to 4, 0 to 6 and 0-8 hours.
|
|
Time to a ≥1-Point Reduction in Numeric Pain Rating Scale (T1PMPR)
Tijdsspanne: 0 to 8 hours post-dose
|
Time from study drug administration to a ≥1-point reduction in pain intensity on the 0-10 NPRS, derived mathematically from scheduled post-dose pain assessments. |
0 to 8 hours post-dose
|
|
Time to a ≥2-Point Reduction in Numeric Pain Rating Scale (T2PMPR)
Tijdsspanne: 0 to 8 hours post-dose
|
Time from study drug administration to a ≥2-point reduction in pain intensity on the 0-10 NPRS, derived mathematically from scheduled post-dose pain assessments. |
0 to 8 hours post-dose
|
|
Time to first use of rescue medication
Tijdsspanne: 0 - 6, 0-8, 0-24 hours post dose.
|
Rescue medication time for SRP-001 compared with placebo |
0 - 6, 0-8, 0-24 hours post dose.
|
|
Total rescue medication consumption
Tijdsspanne: 0 - 6, 0-8, 0-24 hours post dose.
|
Total rescue medication consumption for SRP-001 compared with placebo |
0 - 6, 0-8, 0-24 hours post dose.
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tijdsspanne: Day 1 through Follow-up Visit (Day 8 ± 2 days)
|
Safety as assessed by number of participants with AEs and SAEs for SRP-001 compared with placebo and relationship to study medication |
Day 1 through Follow-up Visit (Day 8 ± 2 days)
|
|
Pain intensity difference (PID) using the 11-point numeric pain rating scale (NPRS)
Tijdsspanne: 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dose
|
Pain intensity difference (PID) Scale is -10 to 10 (higher is better) |
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, and 8 hours post-dose
|
|
Patient's global evaluation of study drug using a 5 point categorical scale
Tijdsspanne: Up to 6 hours post dose
|
Patient's global evaluation of study drug immediately before the first dose of rescue medication, or at early termination (whichever occurs first) using 5 point scale where 0=poor o 4=excellent |
Up to 6 hours post dose
|
|
Number of participants with clinically significant abnormalities in laboratory abnormalities
Tijdsspanne: Screening, Day 1 pre-surgery and follow-up visit, Day 8 ± 2
|
Number of participants with laboratory values judged clinically significant by the investigator in the following panels: Liver function tests (ALT, AST, bilirubin, alkaline phosphatase) Renal function tests (creatinine, BUN) Hematology parameters (CBC with differential) |
Screening, Day 1 pre-surgery and follow-up visit, Day 8 ± 2
|
|
Maximum Observed Plasma Concentration (CMax) of SRP-001
Tijdsspanne: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
CMax of SRP001 following a single 2,000mg oral dose, obtained directly from the plasma concentration data |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Time to maximum observed plasma concentration (Tmax) of SRP-001
Tijdsspanne: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
Tmax of SRP-001 following a single 2,000mg oral dose, obtained directly from the plasma concentration-time data |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Area under the plasma concentration-time curve from 0-12 hours (AUC0-12) of SRP-001
Tijdsspanne: Pre-dose through 12 hours post-dose
|
AUC0-12 of SRP-001 following a single 2,000mg oral dose. |
Pre-dose through 12 hours post-dose
|
|
Area under the plasma concentration time curve from time 0 to the last measurable concentration (AUC0-t) of SRP-001
Tijdsspanne: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
AUC0-t of SRP001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Area under the plasma concentration time curve from time 0 extrapolated to infinity (AUC0-inf) of SRP-001
Tijdsspanne: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
AUC0-inf of SRP-001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Terminal elimination half life (t 1/2) of SRP-001
Tijdsspanne: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
t 1/2 of SRP-001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Apparent oral clearance (CL/F) of SRP-001
Tijdsspanne: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
CL/F of SRP-001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Apparent volume of distribution during the terminal phase (Vx/F) of SRP-001
Tijdsspanne: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
Vz/F of SRP-001 following a single 2,000mg oral dose |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
|
Pain relief Difference (PR) using the 11-point numeric pain rating scale (NPRS)
Tijdsspanne: Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
Pain relief difference (PR) |
Pre-dose and 15, 30, 45 min and 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h post-dose
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Time to first perceptible relief and time to confirmed perceptible pain relief
Tijdsspanne: 0-4.5 hours post dose
|
TPPR and TCPR via stopwatch 1 |
0-4.5 hours post dose
|
|
Time to meaningful relief
Tijdsspanne: 0-4.5 hours post dose
|
TMPR via Stopwatch 2 |
0-4.5 hours post dose
|
|
Time to complete pain relief
Tijdsspanne: 0 to 8 hours post-dose
|
TCOMPR, NPRS = 0 |
0 to 8 hours post-dose
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Todd M Bertoch, MD, CenExel JBR Clinical Research
Publicaties en nuttige links
Algemene publicaties
- Coderch C, Bazan HA, Bazan NG, Surjyadipta B, Alvarez-Builla J, de Pascual-Teresa B. Computational Insights into the Structural Basis for Reduced Hepatotoxicity of Novel Nonopioid Analgesics. ChemMedChem. 2025 Nov 18;20(22):e202500639. doi: 10.1002/cmdc.202500639. Epub 2025 Oct 21.
- Olson AC, Afyusisye F, Egger J, Noyd D, Likonda B, Masalu N, Suneja G, Chao N, Zullig LL, Schroeder K. Cancer incidence and treatment utilization patterns at a regional cancer center in Tanzania from 2008-2016: Initial report of 2,772 cases. Cancer Epidemiol. 2020 Aug;67:101772. doi: 10.1016/j.canep.2020.101772. Epub 2020 Jul 10.
- Bazan HA, Giles BL, Bhattacharjee S, Edwards S, Bazan NG. A non-toxic analgesic elicits cell-specific genomic and epigenomic modulation by targeting the PAG brain region. Neurobiol Pain. 2025 Jul 20;18:100192. doi: 10.1016/j.ynpai.2025.100192. eCollection 2025 Jul-Dec.
- Frelinger AL 3rd, Haynes RL, Goldstein RD, Berny-Lang MA, Gerrits AJ, Riehs M, Haas EA, Paunovic B, Mena OJ, Campman SC, Milne GL, Sleeper LA, Kinney HC, Michelson AD. Dysregulation of platelet serotonin, 14-3-3, and GPIX in sudden infant death syndrome. Sci Rep. 2024 May 15;14(1):11092. doi: 10.1038/s41598-024-61949-9.
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- SRP-001-002
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .